Altos Labs

Altos Labs is a biotechnology company focused on cellular rejuvenation programming, with the ambitious goal of reversing the aging process. Launched in 2022 with $3 billion in funding — the largest biotech debut in history — the company was backed by Jeff Bezos, Yuri Milner, and other prominent investors.

Altos Labs employs leading scientists in the field of epigenetic reprogramming, including Nobel Prize laureate Shinya Yamanaka as a senior scientific advisor. The company's core research uses AI-guided approaches to understand and control Yamanaka factor-mediated cellular reprogramming, which has shown the ability to rejuvenate aged cells and organs in mouse studies. AI and computational biology play a central role in analyzing the molecular pathways of aging and identifying optimal reprogramming strategies.

With research institutes in San Francisco Bay Area, San Diego, Cambridge (UK), and Tokyo, Altos Labs represents one of the largest bets on the convergence of AI and longevity science. Early human safety testing reportedly began in August 2025, marking a critical milestone in translating cellular reprogramming from laboratory research to potential therapeutic applications.